Cargando…
Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors
The lectin pathway (LP) of the complement system is an important antimicrobial defense mechanism, but it also contributes significantly to ischemia reperfusion injury (IRI) associated with myocardial infarct, stroke, and several other clinical conditions. Mannan-binding lectin–associated serine prot...
Autores principales: | Szakács, Dávid, Kocsis, Andrea, Szász, Róbert, Gál, Péter, Pál, Gábor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527154/ https://www.ncbi.nlm.nih.gov/pubmed/30952698 http://dx.doi.org/10.1074/jbc.RA119.008315 |
Ejemplares similares
-
MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked
por: Dobó, József, et al.
Publicado: (2016) -
Directed Evolution-Driven Increase of Structural Plasticity
Is a Prerequisite for Binding the Complement Lectin Pathway Blocking
MASP-Inhibitor Peptides
por: Dürvanger, Zsolt, et al.
Publicado: (2022) -
Synergy of protease-binding sites within the ecotin homodimer is crucial for inhibition of MASP enzymes and for blocking lectin pathway activation
por: Nagy, Zoltán Attila, et al.
Publicado: (2022) -
Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway–mediated disorders
por: Dudler, Thomas, et al.
Publicado: (2023) -
Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model
por: Golomingi, Murielle, et al.
Publicado: (2022)